

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

FDA APPROVAL OF IND FOR UBT251 INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors of the Company is pleased to announce that on 26 September 2023, the investigational new drug application (IND) for UBT251 Injection, a Class 1 innovative drug self-developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly-owned subsidiary of the Company, on indications of adult type 2 diabetes, overweight or obesity, was approved by the U.S. Food and Drug Administration (“FDA”) with IND numbers of 167739 and 167740.

UBT251 is a triple-targeted GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon) receptor agonist independently developed by the Company. The Company is the first enterprise in China and the second enterprise in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1/GIP/GCG prepared by chemical synthetic polypeptide, and has already obtained approval for clinical trials in both China and the US.

In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 26 September 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.